Sage Therapeutics Stock Forecast, Price & News

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 10 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Sage Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View analyst ratings for Sage Therapeutics or view top-rated stocks.

Wall Street analysts have given Sage Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sage Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Sage Therapeutics saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 2,600,000 shares, a drop of 23.5% from the July 29th total of 3,400,000 shares. Based on an average daily trading volume, of 940,100 shares, the short-interest ratio is presently 2.8 days. Currently, 5.1% of the company's stock are short sold.
View Sage Therapeutics' Short Interest.

Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Sage Therapeutics.

Sage Therapeutics, Inc. (NASDAQ:SAGE) released its earnings results on Tuesday, August, 3rd. The biopharmaceutical company reported ($1.83) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.69) by $0.14. The biopharmaceutical company earned $1.60 million during the quarter, compared to the consensus estimate of $2.01 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 26.50% and a net margin of 59.79%. The company's revenue for the quarter was up 45.5% on a year-over-year basis. During the same period in the previous year, the business earned ($2.63) EPS.
View Sage Therapeutics' earnings history.

Sage Therapeutics' stock was trading at $42.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SAGE shares have increased by 9.7% and is now trading at $46.40.
View which stocks have been most impacted by COVID-19.

17 brokers have issued 1-year price objectives for Sage Therapeutics' shares. Their forecasts range from $55.00 to $102.00. On average, they anticipate Sage Therapeutics' share price to reach $82.19 in the next twelve months. This suggests a possible upside of 77.1% from the stock's current price.
View analysts' price targets for Sage Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Sage Therapeutics include Grifols (GRFS), CureVac (CVAC), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Mirati Therapeutics (MRTX), Evotec (EVTCY), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Sarepta Therapeutics (SRPT), Mawson Infrastructure Group (WIZP), Arrowhead Pharmaceuticals (ARWR) and HUTCHMED (HCM).
View all of SAGE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Sage Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (11.67%), Vanguard Group Inc. (8.20%), Jefferies Group LLC (0.00%), BlackRock Inc. (4.85%), Bellevue Group AG (4.02%) and Price T Rowe Associates Inc. MD (2.67%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Barry E Greene, James M Frates and Jeffrey M Jonas.
View institutional ownership trends for Sage Therapeutics.

SAGE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Invesco Ltd., Alliancebernstein L.P., Price T Rowe Associates Inc. MD, Victory Capital Management Inc., BlackRock Inc., Marshall Wace North America L.P., and Great Point Partners LLC.
View insider buying and selling activity for Sage Therapeutics or view top insider-selling stocks.

SAGE stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Bellevue Group AG, Morgan Stanley, Morgan Stanley, Integral Health Asset Management LLC, Dimensional Fund Advisors LP, Citadel Advisors LLC, and Amundi. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas.
View insider buying and selling activity for Sage Therapeutics or or view top insider-buying stocks.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SAGE stock can currently be purchased for approximately $46.40.

Sage Therapeutics has a market capitalization of $2.73 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $606.07 million in net income (profit) each year or ($9.47) on an earnings per share basis.

Sage Therapeutics employs 298 workers across the globe.

The official website for Sage Therapeutics is www.sagerx.com.

Sage Therapeutics is headquartered at 215 FIRST STREET, CAMBRIDGE MA, 02142.

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 299-8380 or via email at [email protected]